The Collective of Experts at Devinebio

Devinebio has assembled a Collective of Experts in drug development. They come from a variety of backgrounds and experiences. The Collective of Experts provides us just-in-time solutions - at the right time and place where they are most needed.

Chris Hopkins, PhD, MBA

Target ID, Drug Discovery, Corporate Relations

Russ Teichert, PhD, MBA

iPSC Assay Development, Drug Screens, High Content imaging

Thomas Caulfield, PhD

Molecular Dynamics Modeling, AI Smart Library Generation

Michelle Mc Guinness, MSc

Regulatory Strategy, Drug Development, Health Authority Liaison

Simon Sydserff, PhD

Drug Discovery, Neurology and cardiology, Disease Model Creation

Y. Shrike Zhang, PhD, MD

Microphysological Systems, Bimedical Engineering, Microfluidics

Immunological Drug Development, Vaccine Therapies in Oncology, iPSC Platforms for Drug Discovery

Priority Review Vouchers, Alternative Funding, Drug Hunting, Startups.

Shantha Tyavanagimatt, PhD

Drug Development GAP assessment, CMC Development and Clinical Pharmacology,

John Lincecum, PhD

Neurodegeneration models, drug discovery and development

Brett Crockett, JD

Patents, IP licensing, Dispute Resolution

Todd Verdoorn, PhD

Neuropharmacology, biomarker development, Statistics

Anne Taylor, PhD

Microfludics, Neuromuscular Junction Models, iPSC-based Systems

Ricky Solorzano

Bioprinting, Vascular 3D models, Venture Architect

Suzanne Hendrix, PhD

Data Managment Services, Statistical Analysis Plans, Strategic Planning

Leah Hustad

Startup Entrepreneur, Life Science Operations, Business Development

Adam Miller, MBS

CDMO Sourcing and Management, CMC Strategic Roadmaps, Process Improvement

Gergley Vertes, MBA

Commercialization Strategy, Asset Partnering, Stakeholder Management

Parth Shah

Rare Disease Commercialization, Product Marketing Strategy, Management and Organizational Build

Ketan Desai, MD, PhD

Clinical Study Design, Regulatory Engagement, Global trials management.

John Bogdan, PhD

Federal Research Projects, Vaccines and Diagnostics Development, Federal Agency Liaison.

The Collective Details

The Collective of Experts team expertise covers Drug-Protein Interaction Modeling, Smart Library Generation, High-throughput and High-content Assay Development, Animal Model Development, FDA Regulatory Filings, Chemistry-Manufacturing-Controls, and Clinical Trials Planning, and more. They help us foster the growth of our Special Purpose Exit Companies (SPECs) where we mature drug assets in a given genetic disease towards market approval. The Collective of Experts also provides efficient drug development solutions for Life Science companies. We aid in commercializing therapeutics for Small Molecules, Biologics and Advanced Therapeutics. This is part of the Devine Process - we accesses expert talent, at the right time, and at the right place of need, to help keep the drug development pipeline on track.

Ready to partner on drug discovery?

Schedule a call with us using the following link: